Early Experience With an Occupational JYNNEOS (Orthopoxvirus) Vaccination Program

被引:1
作者
Swift, Melanie D. [1 ,2 ]
McDermott, Mary C.
Hainy, Caitlin M. [1 ]
Arendt, Christopher J. [3 ]
Anderson, Jennifer A. [1 ]
Mahoo, Jacqueline J. [1 ]
Breeher, Laura E. [1 ,2 ]
机构
[1] Mayo Clin, Occupat Hlth Serv, Rochester, MN 55905 USA
[2] Mayo Clin, Div Publ Hlth, Infect Dis & Occupat Med, Rochester, MN 55905 USA
[3] Mayo Clin, Pharm, Rochester, MN USA
关键词
vaccination; Mpox; JYNNEOS; vaccinia; occupational;
D O I
10.1097/JOM.0000000000002846
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ObjectiveThe aim of the study is to identify lessons learned implementing JYNNEOS vaccination for laboratory workers exposed to orthopoxviruses such as mpox.MethodsWorkers at risk of laboratory exposure were offered vaccine in a carefully planned occupational health program. Vaccine was procured from the Centers for Disease Control and Prevention (CDC) Drug Service, which has special requirements. Reasons for accepting or declining vaccine and adverse effects were obtained by survey.ResultsMost workers accepted JYNNEOS, and occupational risk was the most commonly cited reason for acceptance. Most experienced mild local adverse effects. The administrative requirements of the Centers for Disease Control and Prevention Drug Service are documented.ConclusionsOccupational health programs caring for laboratory workers handling unusual biological agents require careful planning and coordination to facilitate access to vaccines that are not commercially available, anticipate and mitigate barriers to vaccination, and comply with special Centers for Disease Control and Prevention requirements.
引用
收藏
页码:477 / 480
页数:4
相关论文
共 16 条
  • [1] Advisory Committee on Immunization Practices (ACIP), 1980, MMWR MORB MORTAL WKL, V29, P417
  • [2] [Anonymous], 2022, CDC NEWSROOM RELEASE
  • [3] Centers for Disease Control and Prevention, 2022, CDC DRUG SERV
  • [4] Centers for Disease Control and Prevention (U.S.), 1983, MMWR MORB MORTAL WKL, V32, P543
  • [5] Centers for Disease Control and Prevention (U.S.), 2022, REQ IN DOS ERVEBO 20
  • [6] Centers for Disease Control and Prevention (U.S.), 2002, JYNNEOS VACCINE, V21, P247
  • [7] Centers for Disease Control and Prevention (U.S.), 2008, MMWR MORB MORTAL WKL, V57, P207
  • [8] Centers for Disease Control (CDC), 1983, MMWR Morb Mortal Wkly Rep, V32, P387
  • [9] Duffy J, 2022, MMWR-MORBID MORTAL W, V71, P1555, DOI 10.15585/mmwr.mm7149a4
  • [10] Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects
    Frey, Sharon E.
    Wald, Anna
    Edupuganti, Srilatha
    Jackson, Lisa A.
    Stapleton, Jack T.
    El Sahly, Hana
    El-Karnary, Samer S.
    Edwards, Kathryn
    Keyserling, Harry
    Winokur, Patricia
    Keitel, Wendy
    Hill, Heather
    Goll, Johannes B.
    Anderson, Edwin L.
    Graham, Irene L.
    Johnston, Christine
    Mulligan, Mark
    Rouphael, Nadine
    Atmar, Robert
    Patel, Shital
    Chen, Wilbur
    Kotloff, Karen
    Creech, C. Buddy
    Chaplin, Paul
    Belshe, Robert B.
    [J]. VACCINE, 2015, 33 (39) : 5225 - 5234